

F. No. IND/CT/23/000029
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

To
M/s Shilpa Medicare Limited,
Shilpa House 12-6-214/A1,
Hyderabad Road Raichur (India) – 584135.

23 MAY 2023

Subject: Permission to conduct “A phase-III, Randomized, Double-blind, placebo controlled, Multi-center, Parallel group, study to Evaluate the Safety and Efficacy of Nor-Ursodeoxycholic Acid 1500 mg in patients suffering from Non-alcoholic Fatty Liver Disease (NAFLD).” Protocol Number: 001/Nor-UDCA/SML/2023 Version No: 2.0, Date: 18th May 2023 –regarding.

Sir,

With reference to your application, please find enclosed herewith the permission in **Form CT-06, No. CT/ND/23/2023** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019.**

This permission is subject to the conditions, as mentioned below.

Yours faithfully


(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) The informed Consent Document including ICF and Patient Information Sheet should clearly mention in understandable language about the details of the drug therapy that the patient may or may not receive.
- (xx) It may kindly be noted that merely granting permission to conduct Clinical Trial study with drug doesn't convey or imply that based Clinical Trial data generated with the drug, permission to market this drug will automatically be granted to you.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL
NEW DRUG**

The Central Licensing Authority hereby **M/s Shilpa Medicare Limited. Shilpa House 12-6-214/A1, Hyderabad Road Raichur (India) - 584135 Telephone No.: 8532-238704 FAX: 8532238876 E-Mail INFO@VBSHILPA.COM** to conduct clinical trial of the investigational new drug as per **Protocol Number: 001/Nor-UDCA/SML/2023 Version No: 2.0, Date: 18th May 2023** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	Nor-ursodeoxycholic acid tablets 500 mg
Therapeutic class:	Anti-inflammatory
Dosage form:	Tablets
Composition:	Nor-ursodeoxycholic acid.....500 milligram (mg)
Indications:	<ol style="list-style-type: none">1. Indicated for the treatment of non-alcoholic fatty liver disease (NAFLD).2. Primary Biliary Cholangitis.3. The dissolution of cholesterol stones in patients:<ul style="list-style-type: none">• With one or more X-ray radiolucent (X-ray negative) gallstones, preferably with a diameter of not more than 2 cm, in a well-functioning gall bladder.• Refusing a surgical procedure or in which surgical intervention is not indicated.

		<ul style="list-style-type: none"> • With whom an oversaturation of cholesterol has been shown by chemical analysis of the bile produced by duodenum drainage. <p>4. Hepatobiliary disorder associated with cystic fibrosis in children aged years to 18 years.</p>
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
01	<p>Dr. Mahesh Mangulkar, DNB (Gastroenterology), MD (General Medicine)</p> <p>Supre Hospital, Supre Hospital Ethics committee (SHEC) Supre Heart and Diabetes Hospital and Research centre, Opposite Adharashram Gharpure Gha: Near Rungta High School, Ashok Stambh Nasik Maharashtra – 422002.</p>	<p>Supre Hospital Ethics Committee, Supre Heart Diabetes Hospital And Research Centre Opp. Adharashram, Gharpure Ghat Near Rungtha School, Ashok Stambha Nashik Maharashtra - 422002 India.</p> <p>ECR/272/Inst/MH/2013/RR-19</p>
02	<p>Dr. Mandar Doiphode, DNB (Gen. Surgeon), M.N.A. M. S., FMAS, FICS.</p> <p>Sangvi Multispecialty Hospital Pvt. Ltd., Krusha Chouk, Sangvi, Pune. Maharashtra – 411046.</p>	<p>IEC-Sai Sneha Hospital and Diagnostic Centre Sai Sneha Hospital and Diagnostic Centre Opp. PMT Bus Depot Pune Satara Road Katraj Pune Maharashtra - 411046 India.</p> <p>ECR/989/Inst/MH/2017/RR-20</p>
03	<p>Dr. K. Madhu, MD, DM Gastro Consultant Gastroenterologist</p> <p>GMC and GGH, Research wing .2nd Floor, Beside FM Ward, Srikakulam Srikakulam Andhra Pradesh – 532001.</p>	<p>Institutional Ethics Committee Govt. Medical College Govt. General Hospital Balaga Srikakulam Andhra Pradesh - 532001 India.</p> <p>ECR/492/Inst/AP/2013/RR-20</p>

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.


(Dr. Rajeev Singh Raghuvarshi)
Central Licensing Authority

Stamp

Dr. RAJEEV SINGH RAGHUVANSHI
Drugs Controller General (India)
Central Drugs Standard Control Organisation
Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
FDA Bhawan, Kottla Road,
New Delhi (India)

New Delhi

Date:

23 MAY 2023

Dr. RAJEEV SINGH RAGHUVANSHI
Drugs Controller General (India)
Central Drugs Standard Control Organisation
Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
FDA Bhawan, Kottla Road,
New Delhi (India)